FAST Searches for Aging Biomarkers That Respond to Interventions

On September 30, 2026, CNN reported on the Finding Aging Biomarkers by Searching Existing Trials (FAST) project led by Daniel Belsky of Columbia University’s Mailman School of Public Health and the Robert N. Butler Columbia Aging Center.

The goal is to connect intervention responses with healthy life

According to CNN, FAST is collecting molecular data to identify biological indicators that respond to interventions. Its immediate objective is to find useful candidates for measuring changes in aging biology, rather than announce that a particular intervention extends human healthspan. The larger question is whether changes in those indicators reliably predict meaningful outcomes such as disease prevention or longer healthy life. For longevity research, the important advance would be a dependable connection between a measurable biological response and a benefit that matters to people.

The research focuses on human measurements

Evidence type: Human research. FAST searches existing trials, while the related pooled analysis described below examined human intervention studies.

This distinction matters because the project is asking a measurement question within human research: which biological indicators respond when an intervention is tested? Identifying those indicators would give researchers candidates to investigate further. The project’s purpose should therefore be understood as a search for useful research measurements, not as a completed demonstration of improved healthspan.

Belsky’s approach also makes the intervention central to the question. Rather than asking only whether a measurement tracks the passage of time, FAST is looking for indicators that respond to different interventions. Those are related but distinct research goals. A measurement intended to assess an intervention needs evidence about what happens when that intervention is introduced.

FAST combines several kinds of molecular data

CNN reports that FAST is collecting proteins, metabolites and epigenetic marks on white blood cells. The term “multi-omic” describes this combination of different kinds of molecular information. In this project, researchers are bringing those measurements into the same search for responsive indicators rather than restricting the work to a single category.

The epigenetic component includes methyl groups attached to DNA, according to CNN’s explanation. These marks relate to gene regulation without changing the underlying DNA sequence. Belsky told the outlet that they could help researchers “track the passage of time in a human body.” That makes them relevant to the measurement problem FAST is investigating.

The distinction between tracking time and tracking an intervention deserves attention. A researcher might ask whether a marker reflects aging biology or whether it changes after an intervention. A further question concerns the meaning of that response for future health. Keeping those questions separate makes it easier to understand what each stage of the research is designed to establish.

For readers encountering several kinds of aging tests, sorting measurements by what they actually assess provides a useful starting point. In FAST’s case, the relevant categories are explicitly molecular. The research objective is to identify informative responses within those measurements, then determine which candidates deserve further investigation.

Combining data types broadens the search described in CNN’s report. It also makes precise language important: a protein result and an epigenetic result are different measurements even when both appear under the heading of aging biomarkers. “Multi-omic” identifies the research approach. The usefulness of any selected indicator still depends on the question it is meant to answer.

A separate analysis supplies related human evidence

A September 16, 2026 report from Longevity.Technology summarized an analysis pooling 51 human intervention studies with 3,128 blood samples. The analysis assessed 16 epigenetic clocks and 94 other DNA-methylation biomarkers. These figures describe the scope of that separate analysis, not the size or findings of FAST.

The analysis is relevant because it examines intervention-related measurements in humans. It also provides context for the breadth of the methylation-based biomarker search. Rather than treating all such measurements as interchangeable, readers should keep the reported clocks and other DNA-methylation biomarkers distinct from FAST’s broader collection of molecular data.

The useful comparison is between research questions, not between supposed winners. FAST is seeking responsive indicators across several molecular categories. The pooled analysis examined epigenetic clocks and other DNA-methylation biomarkers across intervention studies. Together, these reports show researchers working on how to measure intervention responses while approaching that task through different sets of measurements.

This is also why keeping different aging-clock measurements separate helps when reading a headline about a changed score. The important detail is the measurement used in the reported research. A general reference to “biological age” leaves out information needed to interpret the result.

Health outcomes give the measurement work its purpose

The rationale for this research extends beyond producing more detailed test results. In CNN’s report, Nir Barzilai of Albert Einstein College of Medicine said: “Aging has biology. This biology drives diseases.” His statement explains the motivation for studying shared aging processes, rather than serving as a result from FAST or the pooled analysis.

Within that rationale, a useful biomarker would help researchers understand whether an intervention affects biology relevant to future health. The eventual outcomes of interest include preventing chronic disease and extending healthy life. The molecular measurement is a proposed way to assess part of that process, while the health outcome remains the reason for doing the research.

This distinction gives readers a practical way to organize the evidence. First identify the measurement being investigated. Then identify the outcome the researchers ultimately want to predict. Finally examine the evidence connecting the two, rather than allowing the test’s name to stand in for that connection.

The evidence has specific limits

• Responsiveness is not validated prediction. Belsky told CNN that the link between altering aging biomarkers and extending healthy lifespan has not been established. A marker would need to reliably predict meaningful health outcomes to function as a validated surrogate endpoint. Similarly, Longevity.Technology cautioned that a biomarker moving is not the same as a person becoming biologically younger.
• The FAST account describes a research objective rather than completed validation. CNN reports a project seeking indicators that respond to interventions. That objective should not be rewritten as a finding that FAST has established which interventions slow human aging. The appropriate interpretation is that candidate identification is part of the work being pursued.
• The pooled analysis does not validate the entire multi-omic approach. Its reported measurements were epigenetic clocks and other DNA-methylation biomarkers. Those results should not be presented as evidence that FAST’s combined protein, metabolite and epigenetic strategy has already been validated.
• Meaningful prevention outcomes may take a long time to assess. Belsky told CNN that a trial beginning when participants are in their 40s or 50s might require two or three decades to determine whether an intervention prevents chronic disease. He described a possible trial horizon, not a fixed duration required for every longevity study.
• Animal findings are a separate evidence category. CNN describes researchers manipulating aging biology in organisms from roundworms to mice. Those experiments do not establish that the same interventions extend human healthspan. Belsky told CNN that clinical-trial evidence for extending human healthspan by intervening in aging biology was not yet available.

For someone evaluating a biological-age test claim, the practical question is therefore specific: has a change in this measurement been shown to predict a health outcome that matters? Look for an answer tied to the particular marker and outcome. A claim that a score changed answers a measurement question, not the full question about future health.

A structured way to assess biological-age test claims helps keep the interpretation focused. Identify what was measured and whether the evidence came from humans. Then ask what outcome was studied and how the marker was connected to it. Personal decisions about testing or treatment belong in a discussion with a qualified healthcare professional rather than resting on a score alone.

Validation requires follow-up tied to health outcomes

The next decisive phase is to test whether intervention-linked changes in selected markers reliably predict subsequent disease prevention or longer healthy life in humans.

How AgeAmaze helps

An intervention-sensitive aging score can be mistaken for evidence that a supplement or emerging therapy improves long-term health. AgeAmaze addresses overstated biological-age claims through readable explanations of biomarkers and interventions, helping research-minded adults distinguish established evidence from promising findings and speculative ideas without turning an early measurement into a promise.

Read the research

Sources

1. Can aging be treated like a disease? Scientists are starting ...
2. Half of tested antiaging products moved nothing in new study